Countdown to 2018 CBIIC：
Vice President of Jiangsu Aidea Pharmaceutical Co., Ltd.
Chris Shen, Bachelor from Nanjing University, Master from Michigan Technological University, and Ph.D. in Chemistry from Harvard University. In 1998, Chris started his career in Bristol-Myers Squibb (BMS) with participation in the development of Bcl / Abl kinase inhibitor drug, a new anti-tumor drug, Dasatinib (Sprycel®, launched in 2012). From 2003 to 2012, Chris worked for Gilead Sciences as Medicinal Chemistry Director, and responsible for the development of the hepatitis C virus NS3 protease inhibitor. In 2012, he came back to China and in charge of development of new drug projects as Vice President of R&D in Jiangsu Aidea Pharmaceutical Co., Ltd. Two of the first-in-class candidates got the IND approval, and now respectively in Phase Ⅲ and Phase I clinical trials, with both funded by National Significant New Drugs Development Program . Chris has published 18 articles in professional journals, filed 23 patents among which 6 patents were granted. He has regarded as Expert of China Thousand Talents Program, Expert and leader of Jiangsu Double Plan of Entrepreneurship and Innovation Program.